The amount of milestone payments the Company is entitled to if Ironwood commences with Phase 3 clinical trials.

No definition available.

Name:	depo_MilestonePaymentsFollowingIronwoodCommencesPhase3ClinicalTrials
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront agreement fee received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeeReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront agreement fees, initial product formulation work and milestone payments received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeesInitialProductFormulationWorkAndMilestonePaymentsReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_MallinckrodtIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_JanssenPharmaceuticaNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_IronwoodPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 31, 2014	Aug. 31, 2012	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
License arrangements
Royalty revenue			$ 844	$ 831	$ 985
Mallinckrodt, Inc.
License arrangements
Milestone revenue recognized	$ 1,000
Janssen Pharmaceutica N.V.
License arrangements
Upfront fee received		$ 10,000
Ironwood Pharmaceuticals, Inc.
License arrangements
Upfront fees, initial product formulation work and milestone payments received	$ 3,400
Milestone payment to be received if Ironwood commences with Phase 3 clinical trials			$ 5,000